Eupraxia Pharmaceuticals Q2 EPS Beats Estimate
Eupraxia Pharmaceuticals reports Q2 EPS of $(0.23), beating the estimate of $(0.25)
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.